ACADIA PHARMACEUTICALS INC. Cost of Revenue
ACADIA PHARMACEUTICALS INC. (ACAD) reported Cost of Revenue of $28.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2026-06-30 was $28.32M, a 36.57% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2026-03-31 was $24.79M, a 21.57% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2025-12-31 was $26.23M, a 20.28% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2025-09-30 was $21.65M, a 14.80% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for fiscal 2025 was $89.00M, a 8.75% increase from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for fiscal 2024 was $81.84M, a 96.55% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for fiscal 2023 was $41.64M, a 309.58% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. cost of goods and services sold for fiscal 2022 was $10.17M, a 46.89% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $28.32M 10-Q · filed 2026-08-05 | $53.11M 10-Q · filed 2026-08-05 | $79.33M derived: sum of 3 quarters · filed 2026-08-05 | $100.98M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $24.79M 10-Q · filed 2026-05-07 | $51.02M derived: sum of 2 quarters · filed 2026-05-07 | $72.66M derived: sum of 3 quarters · filed 2026-05-07 | $93.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.87M derived: sum of 2 quarters · filed 2026-02-26 | $68.61M derived: sum of 3 quarters · filed 2026-08-05 | $89.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $21.65M 10-Q · filed 2025-11-06 | $42.38M derived: sum of 2 quarters · filed 2026-08-05 | $62.77M 10-Q · filed 2025-11-06 | $84.58M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $20.73M 10-Q · filed 2026-08-05 | $41.13M 10-Q · filed 2026-08-05 | $62.93M derived: sum of 3 quarters · filed 2026-08-05 | $81.79M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $20.39M 10-Q · filed 2026-05-07 | $42.20M derived: sum of 2 quarters · filed 2026-05-07 | $61.05M derived: sum of 3 quarters · filed 2026-05-07 | $79.28M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $40.66M derived: sum of 2 quarters · filed 2026-02-26 | $58.89M derived: sum of 3 quarters · filed 2026-02-26 | $81.84M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $18.86M 10-Q · filed 2025-11-06 | $37.09M derived: sum of 2 quarters · filed 2025-11-06 | $60.04M 10-Q · filed 2025-11-06 | $77.93M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $18.23M 10-Q · filed 2025-08-07 | $41.18M 10-Q · filed 2025-08-07 | $59.07M derived: sum of 3 quarters · filed 2026-02-26 | $73.69M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $22.95M 10-Q · filed 2025-05-08 | $40.84M derived: sum of 2 quarters · filed 2026-02-26 | $55.46M derived: sum of 3 quarters · filed 2026-02-26 | $62.92M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $17.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.51M derived: sum of 2 quarters · filed 2026-02-26 | $39.97M derived: sum of 3 quarters · filed 2026-02-26 | $41.64M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $14.62M 10-Q · filed 2024-11-07 | $22.08M derived: sum of 2 quarters · filed 2024-11-07 | $23.75M 10-Q · filed 2024-11-07 | $26.16M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $7.46M 10-Q · filed 2024-08-07 | $9.13M 10-Q · filed 2024-08-07 | $11.54M derived: sum of 3 quarters · filed 2025-02-27 | $13.68M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $1.67M 10-Q · filed 2024-05-09 | $4.08M derived: sum of 2 quarters · filed 2025-02-27 | $6.22M derived: sum of 3 quarters · filed 2025-02-27 | $8.88M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.55M derived: sum of 2 quarters · filed 2025-02-27 | $7.22M derived: sum of 3 quarters · filed 2025-02-27 | $10.17M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $2.14M 10-Q · filed 2023-11-03 | $4.80M derived: sum of 2 quarters · filed 2023-11-03 | $7.75M 10-Q · filed 2023-11-03 | $18.50M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $2.67M 10-Q · filed 2023-08-03 | $5.62M 10-Q · filed 2023-08-03 | $16.36M derived: sum of 3 quarters · filed 2024-02-28 | $20.05M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $2.95M 10-Q · filed 2023-05-08 | $13.69M derived: sum of 2 quarters · filed 2024-02-28 | $17.38M derived: sum of 3 quarters · filed 2024-02-28 | $19.91M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $10.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $14.43M derived: sum of 2 quarters · filed 2024-02-28 | $16.96M derived: sum of 3 quarters · filed 2024-02-28 | $19.14M 10-K · filed 2024-02-28 | $10.84M 10-K · filed 2022-03-01 |
| 2021-09-30 | $3.69M 10-Q · filed 2022-11-03 | $6.21M derived: sum of 2 quarters · filed 2022-11-03 | $8.40M 10-Q · filed 2022-11-03 | $10.91M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $2.53M 10-Q · filed 2022-08-09 | $4.71M 10-Q · filed 2022-08-09 | $7.22M derived: sum of 3 quarters · filed 2023-02-28 | $9.22M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $2.19M 10-Q · filed 2022-05-05 | $4.69M derived: sum of 2 quarters · filed 2023-02-28 | $6.70M derived: sum of 3 quarters · filed 2023-02-28 | $9.60M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.51M derived: sum of 2 quarters · filed 2023-02-28 | $7.41M derived: sum of 3 quarters · filed 2023-02-28 | $10.21M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-09 | $4.90M derived: sum of 2 quarters · filed 2021-11-09 | $7.70M 10-Q · filed 2021-11-09 | $10.72M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $2.90M 10-Q · filed 2021-08-05 | $5.70M 10-Q · filed 2021-08-05 | $8.72M derived: sum of 3 quarters · filed 2022-03-01 | $11.13M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $2.80M 10-Q · filed 2021-05-06 | $5.82M derived: sum of 2 quarters · filed 2022-03-01 | $8.23M derived: sum of 3 quarters · filed 2022-03-01 | $11.19M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.44M derived: sum of 2 quarters · filed 2022-03-01 | $8.39M derived: sum of 3 quarters · filed 2022-03-01 | $11.34M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $2.42M 10-Q · filed 2020-11-04 | $5.37M derived: sum of 2 quarters · filed 2020-11-04 | $8.32M 10-Q · filed 2020-11-04 | $11.15M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $2.96M 10-Q · filed 2020-08-06 | $5.91M 10-Q · filed 2020-08-06 | $8.73M derived: sum of 3 quarters · filed 2021-02-25 | $12.57M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $2.95M 10-Q · filed 2020-05-08 | $5.77M derived: sum of 2 quarters · filed 2021-02-25 | $9.61M derived: sum of 3 quarters · filed 2021-02-25 | $13.17M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $6.66M derived: sum of 2 quarters · filed 2021-02-25 | $10.22M derived: sum of 3 quarters · filed 2021-02-25 | $12.38M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $3.84M 10-Q · filed 2019-10-31 | $7.40M derived: sum of 2 quarters · filed 2019-10-31 | $9.55M 10-Q · filed 2019-10-31 | $12.01M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $3.56M 10-Q · filed 2019-08-01 | $5.71M 10-Q · filed 2019-08-01 | $8.17M derived: sum of 3 quarters · filed 2020-02-27 | $10.30M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | $2.15M 10-Q · filed 2019-05-02 | $4.61M derived: sum of 2 quarters · filed 2020-02-27 | $6.74M derived: sum of 3 quarters · filed 2020-02-27 | $8.97M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $4.59M derived: sum of 2 quarters · filed 2020-02-27 | $6.81M derived: sum of 3 quarters · filed 2020-02-27 | $9.08M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $2.13M 10-Q · filed 2018-11-06 | $4.36M derived: sum of 2 quarters · filed 2018-11-06 | $6.62M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $2.22M 10-Q · filed 2018-08-08 | $4.49M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |